If your GEP-NET has been graded as Grade 3, you may have been told that PRRT is not for you. But that's not always true. Whether lutetium Lu-177 dotatate (brand name Lutathera) is still an option depends less on your Ki-67 number and more on one key question: does your tumor still express somatostatin receptors? A Ga-68 DOTATATE PET scan can answer this. This article is for patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) and their families who want to understand how tumor grade relates to PRRT (peptide receptor radionuclide therapy) eligibility and what to ask next.
What High-Grade Means for Your GEP-NET
Doctors grade GEP-NETs based on how fast tumor cells divide. A marker called Ki-67 measures this - it shows what percentage of cells are actively growing. The World Health Organization uses Ki-67 to define three grades:
- Grade 1: Ki-67 under 3%. Slow-growing.
- Grade 2: Ki-67 between 3% and 20%. Moderate pace.
- Grade 3: Ki-67 above 20%. Faster-growing.
Grade 3 is sometimes called high grade. But Grade 3 is not one disease. There are two very different tumor types under that label. Knowing which one you have matters for your treatment options. Your pathology report - and ideally a specialist review - can help clarify which category your tumor falls into.
Grade 3 NET and Neuroendocrine Carcinoma Are Not the Same Disease
This distinction matters for PRRT eligibility in high-grade disease.
A well-differentiated Grade 3 NET (also called NET G3) is still a neuroendocrine tumor. Under the microscope, the cells look organized. They usually carry somatostatin receptors on their surface, though not always. Ki-67 is typically between 20% and 55%, though it varies.
A neuroendocrine carcinoma (NEC), by contrast, is a poorly differentiated tumor. The cells look disorganized. They usually lose their somatostatin receptors. Ki-67 is often above 55% and sometimes much higher. NECs grow faster and behave more like small cell or large cell carcinomas than classic neuroendocrine tumors. According to the Neuroendocrine Tumor Research Foundation, pathologists look at more than the Ki-67 alone. They also assess how cells are organized and may use additional molecular testing to tell NET G3 apart from NEC.
Doctors designed PRRT to target somatostatin receptors. If those receptors are largely absent, the therapy has no target. This is why poorly differentiated NEC is generally not suitable for lutetium Lu-177 dotatate. But if your report says well-differentiated Grade 3 NET, you may still have meaningful receptor expression - and that changes your options.
Why Your DOTATATE PET Result Carries More Weight Than Your Ki-67 Number
PRRT works because lutetium Lu-177 dotatate attaches to somatostatin receptors on tumor cells and delivers focused radiation directly to them. This means the therapy can only work if those receptors are present in meaningful amounts.
Grade 1 and Grade 2 NETs usually have strong somatostatin receptor expression. In Grade 3, it varies. Some Grade 3 NETs clearly express receptors. Others have partly or fully lost them. The Ki-67 number alone does not tell you which group you are in.
A Ga-68 DOTATATE PET scan (also called DOTATATE PET/CT) can show whether your tumors take up the DOTATATE tracer. The scan uses a small amount of a radioactive substance that binds to somatostatin receptors. If your scan shows clear uptake where your tumors are, receptors are likely present and PRRT could potentially reach those cells.
If your scan shows little or no uptake, PRRT is unlikely to work - regardless of your grade number.
Some patients with high-grade disease have both a DOTATATE PET and an FDG-PET scan. FDG-PET measures glucose uptake and reflects how active a tumor is. When a tumor is highly active on FDG-PET but shows little uptake on DOTATATE PET, this often means the tumor's receptors have likely changed. Our guide to how Ga-68 DOTATATE PET determines PRRT eligibility explains what different scan results mean in plain language.
What the NETTER-2 Trial Showed for Grade 3 GEP-NETs
For years, the main trial evidence for lutetium Lu-177 dotatate came from the NETTER-1 trial, which studied mainly Grade 1 and Grade 2 midgut NETs. NETTER-1 showed better progression-free survival than high-dose octreotide and led to FDA approval of Lutathera in 2018 for somatostatin-receptor-positive GEP-NETs in adults.
The NETTER-2 trial changed the conversation about Grade 3 disease.
NETTER-2 was the first Phase 3 study testing lutetium Lu-177 dotatate as a first-line treatment (before trying other systemic therapies). It enrolled patients with advanced well-differentiated Grade 2 and Grade 3 GEP-NETs that expressed somatostatin receptors. Notably, this included Grade 3 well-differentiated NET patients.
When results came out at the ASCO Gastrointestinal Cancers Symposium in January 2024, they stood out. Patients treated with lutetium Lu-177 dotatate plus long-acting octreotide had a median progression-free survival of 22.8 months. Those treated with octreotide alone had a median of 8.5 months. That's more than 14 months longer before disease progression.
According to the National Cancer Institute, NETTER-2 was the first positive Phase 3 trial testing radioligand therapy in an earlier treatment setting for this patient group. According to ASCO, the trial also showed similar rates of side effects and quality-of-life measures between the two groups, which matters when patients consider safety alongside how well treatment works.
For Grade 3 well-differentiated NETs with confirmed somatostatin receptor expression, NETTER-2 shows that PRRT may be an option.
When PRRT Is Typically Not Recommended for High-Grade Disease
There are several situations where most NET specialists would steer away from PRRT as the next step.
- Poorly differentiated NEC confirmed on pathology. If your biopsy report specifically describes your tumor as poorly differentiated neuroendocrine carcinoma, somatostatin receptors are typically absent or very low. Your team would likely consider other treatment paths first.
- Little or no uptake on DOTATATE PET. If the scan does not show clear uptake in your tumor sites, PRRT would not have an effective target - regardless of your Ki-67 level.
- High FDG-PET activity with low DOTATATE uptake. This pattern often suggests the tumor has shifted to a more aggressive biology that won't respond well to receptor-targeted therapy.
- Insufficient organ function. PRRT involves four intravenous infusions roughly eight weeks apart. You need adequate kidney function, bone marrow reserves, and overall fitness to complete the full course safely. If these are significantly reduced, PRRT may not be safe until they improve.
None of these are absolute rules, and individual cases can be complex. A thorough review by an experienced NET team might change the answer.
What Other Options May Be Available
If PRRT has been ruled out at this stage, there are active treatment approaches for high-grade GEP-NETs worth discussing with your team.
For poorly differentiated NEC, platinum-based chemotherapy combined with etoposide has been the standard first-line approach. Research continues into combinations and newer agents that may improve outcomes for this group.
For well-differentiated Grade 3 NETs, your options are broader. Your oncologist may suggest capecitabine with temozolomide (sometimes called CAPTEM), long-acting somatostatin analogues, or everolimus (an oral therapy). Clinical trials are also testing PRRT in Grade 3 well-differentiated NETs. The COMPOSE study, for example, is comparing lutetium Lu-177 edotreotide versus standard care in patients with well-differentiated Grade 2 and Grade 3 GEP-NETs.
Treatment decisions in this setting are increasingly tailored to each person. The same Ki-67 number means different things depending on the tumor. If you've been told your options are limited, our guide on GEP-NET second-line therapy when PRRT is not an option covers other paths worth discussing with your team.
How to Find Out If PRRT Is Still on the Table for You
If you have a Grade 3 GEP-NET and are not sure whether PRRT is still a realistic option, here is what to focus on.
Check what your pathology report says about differentiation. The words well-differentiated or poorly differentiated carry more clinical weight than the Ki-67 number alone. If your report does not clearly state this, ask your oncologist or request a pathology re-review at a NET center. It is a reasonable ask and an important one.
Ask about a Ga-68 DOTATATE PET scan if you have not had one recently. Somatostatin receptor expression can change over time, especially in Grade 3 disease. A scan from more than 12 to 18 months ago may not reflect your current tumor biology. An up-to-date DOTATATE PET result is the most direct way to assess whether PRRT has a viable target in your case.
Seek a second opinion from a NET specialist or nuclear medicine team. Not all cancer centers have deep experience with GEP-NETs and PRRT. A team that sees high volumes of NET cases - or specifically offers PRRT - may interpret the same scan and pathology report differently. Some patients initially told they were not PRRT candidates have found a different answer after a full multidisciplinary review. If you want an independent look at your case, you can request a second opinion through Art of Healing Cancer on whether Lu-177 is right for you (and what alternatives exist if not).
Ask about clinical trials. For Grade 3 NETs specifically, several trials are recruiting patients with somatostatin-receptor-positive tumors. Eligibility criteria vary widely. A NET specialist can advise whether a trial might be a better path than standard care for your situation.
If you would like your current DOTATATE PET results and pathology reviewed by a team with experience in PRRT eligibility assessments, you can reach out through the Lutetium Therapy contact page. If lutetium Lu-177 dotatate is not the right fit for your case, a second opinion on what is available may be just as valuable.
When to Talk to Your Doctor
Speak with your oncologist or a NET specialist if you have a Grade 3 GEP-NET diagnosis and have not yet had a Ga-68 DOTATATE PET scan. Raise PRRT eligibility with your team if your pathology report describes your tumor as well-differentiated but the option has not been discussed. Ask for a second opinion if you have been told PRRT is not an option but no DOTATATE PET was done to confirm low receptor expression. And if your current treatment is no longer controlling the disease, ask directly what the next line of options looks like - including whether PRRT may now apply to your case.
This article is for general information and is not a substitute for medical advice. Always consult your oncologist or care team about your specific situation.
Frequently asked questions
Can patients with Grade 3 GEP-NETs qualify for PRRT with Lu-177 DOTATATE?
Some can, yes. Eligibility is not decided by grade alone. Patients with well-differentiated Grade 3 NETs that still express somatostatin receptors - confirmed by a Ga-68 DOTATATE PET scan - may qualify for PRRT. The NETTER-2 trial, presented in 2024, included Grade 3 well-differentiated NET patients and showed a significant improvement in progression-free survival with lutetium Lu-177 dotatate compared to octreotide alone. Patients with poorly differentiated neuroendocrine carcinoma (NEC) are generally not suitable candidates, because those tumors have typically lost somatostatin receptor expression.
What is the difference between a Grade 3 NET and a neuroendocrine carcinoma?
They are related but biologically different. A well-differentiated Grade 3 NET still has an organized cell structure under the microscope and often retains somatostatin receptors. Ki-67 is typically between 20% and 55%. A poorly differentiated neuroendocrine carcinoma (NEC) has disorganized cells, usually a much higher Ki-67, and has typically lost somatostatin receptor expression. This distinction matters greatly for treatment: PRRT targets somatostatin receptors, so it is far more likely to be applicable to Grade 3 NET than to NEC. Your pathology report should specify which category you are in, and if it is not clear, a specialist review can help.
Why does the DOTATATE PET scan matter so much for Grade 3 GEP-NET patients?
Because PRRT only works if the tumors express somatostatin receptors - and in Grade 3 disease, that expression is variable. A Ga-68 DOTATATE PET scan directly shows whether your tumors absorb the DOTATATE tracer, which is a reliable indicator of receptor presence. In lower grades, receptor expression is usually strong and a positive scan is common. In Grade 3, the scan result is less predictable, so it is the most important single piece of information for determining whether PRRT is feasible. A negative DOTATATE PET generally means PRRT would not have an adequate target, regardless of other factors.
What did the NETTER-2 trial find for Grade 3 GEP-NET patients?
NETTER-2 was the first Phase 3 randomized trial to test lutetium Lu-177 dotatate as a first-line treatment - meaning before other systemic therapies. It included patients with well-differentiated Grade 2 and Grade 3 advanced GEP-NETs expressing somatostatin receptors. Patients who received lutetium Lu-177 dotatate plus long-acting octreotide had a median progression-free survival of 22.8 months, compared to 8.5 months with octreotide alone. The Grade 3 subgroup was part of the enrolled population. These results were presented at the ASCO Gastrointestinal Cancers Symposium in January 2024 and represent an important shift in how Grade 3 disease is approached.
If PRRT is not suitable for my high-grade NET, what other treatments might be available?
For poorly differentiated neuroendocrine carcinoma (NEC), platinum-based chemotherapy combined with etoposide has typically been the standard first-line option. For well-differentiated Grade 3 NETs where PRRT is not currently applicable, options may include capecitabine plus temozolomide (CAPTEM), everolimus (an oral targeted therapy), somatostatin analogues, or enrollment in a clinical trial. The COMPOSE study, for example, is evaluating lutetium Lu-177 edotreotide in patients with well-differentiated high Grade 2 and Grade 3 GEP-NETs. Treatment decisions in this setting are highly individualized, and consulting a multidisciplinary NET team is the best way to understand what fits your specific tumor biology.
Should I get a second opinion if I was told PRRT is not an option for my Grade 3 GEP-NET?
A second opinion is worth considering, particularly if no Ga-68 DOTATATE PET scan was done before the conclusion was reached, or if the review was not carried out at a center with NET-specific expertise. PRRT eligibility in Grade 3 disease is nuanced - it depends on differentiation status, receptor expression, and overall clinical picture. A nuclear medicine team or NET center that regularly performs PRRT may assess the same pathology and imaging differently. Some patients initially told they were not candidates have been found eligible after a full case review.
